Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Melanoma
Conditions
Melanoma
Trial Timeline
Aug 1, 2006 → Dec 13, 2013
NCT ID
NCT00365937About Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321
Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321 is a phase 1/2 stage product being developed by Immutep for Melanoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00365937. Target conditions include Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00365937 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Binimetinib Oral Tablet | Biotrial | Phase 1 | 25 |
| Tasisulam-sodium + Paclitaxel | Eli Lilly | Phase 3 | 77 |
| [203Pb]VMT01 + [212Pb]VMT01 + Nivolumab | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT01 + [68Ga]VMT02 | Perspective Therapeutics | Phase 1 | 25 |
| FYB206 + Keytruda | Formycon AG | Phase 1 | 25 |
| PLX3397 | Daiichi Sankyo | Pre-clinical | 23 |
| PLX3397 + Pembrolizumab | Daiichi Sankyo | Phase 1/2 | 41 |
| Trastuzumab deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| DS-8273a + Nivolumab | Daiichi Sankyo | Phase 1 | 33 |
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| enfortumab vedotin + pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| YM155 | Astellas Pharma | Phase 2 | 52 |
| YM155 + Docetaxel | Astellas Pharma | Phase 2 | 52 |
| Denileukin diftitox | Eisai | Phase 2 | 52 |
| E7080 | Eisai | Phase 1 | 33 |
| lenvatinib + pembrolizumab | Eisai | Phase 2 | 52 |
| MORAb-004 (monoclonal antibody) | Eisai | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 52 |
| Lenvatinib + Lenvatinib + Dacarbazine | Eisai | Phase 1/2 | 41 |
Other Products from Immutep
eftilagimod alpha + PaclitaxelPhase 2/3
57
Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.vPhase 2
44
Pembrolizumab, Eftilagimod alfaPhase 2
44
IMP321 (eftilagimod alpha) + Placebo + PaclitaxelPhase 2
44
2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbsPhase 1/2
33